Inhibition of cathepsin K for treatment of osteoporosis (Q37974148)

26 August 2017

title

Inhibition of cathepsin K for treatment of osteoporosis (English)

1 reference

26 August 2017

0 references

Steven Boonen

1

1 reference

26 August 2017

Elizabeth Rosenberg

2

1 reference

26 August 2017

Frank Claessens

3

1 reference

26 August 2017

Dirk Vanderschueren

4

1 reference

26 August 2017

Socrates Papapoulos

5

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Current osteoporosis reports

26 August 2017

published in

1 reference

26 August 2017

volume

10

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

73-79

1 reference

Osteoporosis: now and the future

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Epidemiology and outcomes of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Osteoclast lineage and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Biochemical properties and regulation of cathepsin K activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Are nonresorbing osteoclasts sources of bone anabolic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Local communication on and within bone controls bone remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Osteoclast-osteoblast communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Functions of RANKL/RANK/OPG in bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Eph-ephrin bidirectional signaling in physiology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Bone density, strength, and formation in adult cathepsin K (-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Cathepsin K inhibitors: a novel target for osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Drug-induced morphea: report of a case induced by balicatib and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Relation between age, femoral neck cortical stability, and hip fracture risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0085-9

Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K

21 January 2018

1 reference

12 December 2020

High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K

1 reference

12 December 2020

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

1 reference

12 December 2020

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

1 reference

12 December 2020

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

1 reference

12 December 2020

Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein

1 reference

12 December 2020

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study

1 reference

12 December 2020

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib

1 reference

12 December 2020

10.1007/S11914-011-0085-9

Identifiers

DOI

1 reference

26 August 2017

1 reference